New approach could reduce harsh drug side effects for transplant patients fighting CMV
NCT ID NCT06407232
First seen Nov 01, 2025 · Last updated Apr 15, 2026 · Updated 19 times
Summary
This study is testing whether a drug called letermovir can prevent cytomegalovirus (CMV) infections from coming back in high-risk kidney or kidney/pancreas transplant patients. Researchers want to see if switching to letermovir earlier than usual can reduce the time patients need to take a stronger drug that often causes significant side effects. The study will also check if this approach helps the patients' own immune systems develop better protection against future CMV infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYTOMEGALOVIRUS INFECTIONS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
UW Hospital and Clinics
RECRUITINGMadison, Wisconsin, 53792, United States
Contact
Contact
Contact
Conditions
Explore the condition pages connected to this study.